Successful Analysis Demonstrates Effective Bioactivation of Colon-Specific PDE4 Inhibitor Prodrug
Palisade Bio (PALI), a biopharmaceutical firm dedicated to advancing therapies for autoimmune, inflammatory, and fibrotic diseases, announces positive outcomes from its analysis of PALI-2108, an oral colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug for ulcerative colitis (UC) patients.
The study, conducted in collaboration with Altasciences, confirms PALI-2108’s efficient conversion into its active form within stool samples from both healthy individuals and UC patients. LC-MS analysis revealed a mean conversion rate of 90.1% within a 24-hour timeframe, signaling the drug’s potential efficacy in managing UC.
Dr. Mitch Jones, Palisade Bio’s CMO, expresses confidence in PALI-2108 as a targeted UC therapy, emphasizing its consistent and robust bioactivation profile. These findings underscore the drug’s promise as an innovative treatment option for moderate-to-severe UC, offering hope for patients seeking effective disease management strategies.
Read original press release:here
You might like this article:Lockheed Martin Secures $17 Billion Contract for Next-Gen Interceptors
